Literature DB >> 7047672

Fibronectin is produced by blood vessels in response to injury.

R A Clark, J H Quinn, H J Winn, J M Lanigan, P Dellepella, R B Colvin.   

Abstract

During the time of tissue repair that ensues subsequent to tissue injury, blood vessel wall fibronectin increases concomitantly with endothelial proliferation and angiogenesis. However, the source of this blood vessel fibronectin had not been delineated. In this report we have demonstrated that microvascular fibronectin is produced in situ by the proliferating vessels surrounding excisional wounds. This finding was established by extirpating 3 mm of skin from the center of a well-healed rat xenograph on the flanks of immunosuppressed mice, harvesting the injured skin sites at various stages during the healing process, and staining the specimens with reciprocal species-specific anti-fibronectin. The proliferating donor vessels that surrounded the wounded graft had increased fluorescence staining with FITC conjugated mouse anti-rat fibronectin and no staining with rat anti-mouse fibronectin. This finding was taken as direct evidence that the fibronectin was produced in situ by the rat vessels and not derived from circulating mouse plasma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047672      PMCID: PMC2186773          DOI: 10.1084/jem.156.2.646

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Binding of soluble form of fibroblast surface protein, fibronectin, to collagen.

Authors:  E Engvall; E Ruoslahti
Journal:  Int J Cancer       Date:  1977-07-15       Impact factor: 7.396

3.  Plasma membrane glycoprotein which mediates adhesion of fibroblasts to collagen.

Authors:  E Pearlstein
Journal:  Nature       Date:  1976-08-05       Impact factor: 49.962

4.  Metabolic fate of the major cell surface protein of normal human fibroblasts.

Authors:  B J Baum; J A McDonald; R G Crystal
Journal:  Biochem Biophys Res Commun       Date:  1977-11-07       Impact factor: 3.575

5.  Alteration of cell-surface proteins by viral transformation and by proteolysis.

Authors:  R O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  1973-11       Impact factor: 11.205

6.  Isolation of a major cell surface glycoprotein from fibroblasts.

Authors:  K M Yamada; J A Weston
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

7.  Isolation of a collagen-dependent cell attachment factor.

Authors:  R J Klebe
Journal:  Nature       Date:  1974-07-19       Impact factor: 49.962

8.  Novel human serum protein from fibroblast plasma membrane.

Authors:  E Ruoslahti; A Vaheri
Journal:  Nature       Date:  1974-04-26       Impact factor: 49.962

9.  Synthesis of cold-insoluble globulin by cultured calf endothelial cells.

Authors:  E J Macarak; E Kirby; T Kirk; N A Kefalides
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

10.  Distribution of fibroblast surface antigen in the developing chick embryo.

Authors:  E Linder; A Vaheri; E Ruoslahti; J Wartiovaara
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  41 in total

1.  Intravital microscopy identifies selectins that regulate T cell traffic into allografts.

Authors:  Thomas R Jones; Nozomu Shirasugi; Andrew B Adams; Thomas C Pearson; Christian P Larsen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

2.  Bacterial infection of wounds: fibronectin-mediated adherence group A and C streptococci to fibrin thrombi in vitro.

Authors:  G S Chhatwal; P Valentin-Weigand; K N Timmis
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

3.  Fight-or-flight: murine unilateral ureteral obstruction causes extensive proximal tubular degeneration, collecting duct dilatation, and minimal fibrosis.

Authors:  Michael S Forbes; Barbara A Thornhill; Jordan J Minor; Katherine A Gordon; Carolina I Galarreta; Robert L Chevalier
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-25

Review 4.  Metalloproteinases and their inhibitors: regulators of wound healing.

Authors:  Sean E Gill; William C Parks
Journal:  Int J Biochem Cell Biol       Date:  2007-10-26       Impact factor: 5.085

5.  Fibronectin deposition in delayed-type hypersensitivity. Reactions of normals and a patient with afibrinogenemia.

Authors:  R A Clark; C R Horsburgh; A A Hoffman; H F Dvorak; M W Mosesson; R B Colvin
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

6.  Cryptic activity within the Type III1 domain of fibronectin regulates tissue inflammation and angiogenesis.

Authors:  Christina Cho; Rhiannon Kelsh-Lasher; Anthony Ambesi; Paula J McKeown-Longo
Journal:  Curr Top Pept Protein Res       Date:  2015

7.  Fibronectin fibrillogenesis regulates three-dimensional neovessel formation.

Authors:  Xiaoming Zhou; R Grant Rowe; Nobuaki Hiraoka; Jerry P George; Denis Wirtz; Deane F Mosher; Ismo Virtanen; Michael A Chernousov; Stephen J Weiss
Journal:  Genes Dev       Date:  2008-05-01       Impact factor: 11.361

8.  Fibronectin in chronic inflammation: studies using the rat air pouch model of chronic allergic inflammation.

Authors:  D L Scott; M W Robinson; S Yoshino
Journal:  Br J Exp Pathol       Date:  1985-10

9.  The accumulation of inflammatory cells in synovial sheath and epitenon during adhesion formation in healing rat flexor tendons.

Authors:  B Wojciak; J F Crossan
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

10.  Increased expression of fibronectin and the alpha 5 beta 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia.

Authors:  Richard Milner; Stephanie Hung; Bernadette Erokwu; Paula Dore-Duffy; Joseph C LaManna; Gregory J del Zoppo
Journal:  Mol Cell Neurosci       Date:  2008-02-13       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.